279 related articles for article (PubMed ID: 25588356)
21. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
22. Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein.
Schidlitzki A; Stanojlovic M; Fournier C; Käufer C; Feja M; Gericke B; Garzotti M; Welford RWD; Steiner MA; Angot E; Richter F
Mov Disord; 2023 Jun; 38(6):1044-1055. PubMed ID: 37050861
[TBL] [Abstract][Full Text] [Related]
23. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.
Chesselet MF; Richter F; Zhu C; Magen I; Watson MB; Subramaniam SR
Neurotherapeutics; 2012 Apr; 9(2):297-314. PubMed ID: 22350713
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
26. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits.
Hatami A; Chesselet MF
Curr Top Behav Neurosci; 2015; 22():303-30. PubMed ID: 25218491
[TBL] [Abstract][Full Text] [Related]
27. Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.
Dirr ER; Ekhator OR; Blackwood R; Holden JG; Masliah E; Schultheis PJ; Fleming SM
Behav Brain Res; 2018 May; 343():41-49. PubMed ID: 29407413
[TBL] [Abstract][Full Text] [Related]
28. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
[TBL] [Abstract][Full Text] [Related]
29. Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson's Disease as a Multi-System Process.
Videlock EJ; Hatami A; Zhu C; Kawaguchi R; Chen H; Khan T; Yehya AHS; Stiles L; Joshi S; Hoffman JM; Law KM; Rankin CR; Chang L; Maidment NT; John V; Geschwind DH; Pothoulakis C
J Parkinsons Dis; 2023; 13(7):1127-1147. PubMed ID: 37638450
[TBL] [Abstract][Full Text] [Related]
30. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
31. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons.
Cabeza-Arvelaiz Y; Fleming SM; Richter F; Masliah E; Chesselet MF; Schiestl RH
Mol Neurodegener; 2011 Dec; 6():83. PubMed ID: 22165993
[TBL] [Abstract][Full Text] [Related]
32. Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61") transgenic mouse line.
Delenclos M; Carrascal L; Jensen K; Romero-Ramos M
Neuroscience; 2014 Sep; 277():647-64. PubMed ID: 25090921
[TBL] [Abstract][Full Text] [Related]
33. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.
Fernagut PO; Hutson CB; Fleming SM; Tetreaut NA; Salcedo J; Masliah E; Chesselet MF
Synapse; 2007 Dec; 61(12):991-1001. PubMed ID: 17879265
[TBL] [Abstract][Full Text] [Related]
34. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
[TBL] [Abstract][Full Text] [Related]
35. GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease.
Ikuno M; Yamakado H; Akiyama H; Parajuli LK; Taguchi K; Hara J; Uemura N; Hatanaka Y; Higaki K; Ohno K; Tanaka M; Koike M; Hirabayashi Y; Takahashi R
Hum Mol Genet; 2019 Jun; 28(11):1894-1904. PubMed ID: 30689867
[TBL] [Abstract][Full Text] [Related]
36. Impact of DHA intake in a mouse model of synucleinopathy.
Coulombe K; Kerdiles O; Tremblay C; Emond V; Lebel M; Boulianne AS; Plourde M; Cicchetti F; Calon F
Exp Neurol; 2018 Mar; 301(Pt A):39-49. PubMed ID: 29229294
[TBL] [Abstract][Full Text] [Related]
37. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
38. FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.
Vidal-Martínez G; Vargas-Medrano J; Gil-Tommee C; Medina D; Garza NT; Yang B; Segura-Ulate I; Dominguez SJ; Perez RG
J Biol Chem; 2016 Sep; 291(39):20811-21. PubMed ID: 27528608
[TBL] [Abstract][Full Text] [Related]
39. Young human alpha synuclein transgenic (BAC-SNCA) mice display sex- and gene-dose-dependent phenotypic disturbances.
Moceri S; Bäuerle N; Habermeyer J; Ratz-Wirsching V; Harrer J; Distler J; Schulze-Krebs A; Timotius IK; Bluhm A; Hartlage-Rübsamen M; Roßner S; Winkler J; Xiang W; Hörsten SV
Behav Brain Res; 2024 Mar; 460():114781. PubMed ID: 38043677
[TBL] [Abstract][Full Text] [Related]
40. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Petit GH; Berkovich E; Hickery M; Kallunki P; Fog K; Fitzer-Attas C; Brundin P
PLoS One; 2013; 8(4):e60691. PubMed ID: 23573275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
